Naik Meditechs

HbA1C - Bayer Home Test / Professional Test Strips

2009-07-14T04:08:00.001-07:00

What is A1C?
The A1C test is also called glycated hemoglobin, HbA1c, or glycosylated hemoglobin. A1C provides an indication of your patient’s average blood glucose control for the past 2-3 months. Hemoglobin is part of the red blood cells and binds to glucose. The A1C complex is formed when the glucose in the blood binds irreversibly (glycates) to hemoglobin. The higher the glucose level in the blood, the more that binds to the hemoglobin. Therefore, A1C values are proportional to the amount of glucose in the blood. The A1C result is in percentage (%) units and reflects the percentage of the hemoglobin that is glycated.

Hemoglobin remains glycated for the lifespan of the red blood cell, about 90-120 days. Therefore, the A1C test reflects an average blood glucose control for the past 2-3 months. Mean blood glucose of the 30 days prior to the A1C test contributes to 50% of the A1C value.

Fasting plasma glucose contributes more to A1C results in patients with poorly controlled diabetes. In satisfactory to good control of diabetes, postprandial glucose is the predominant contributor.

The American Diabetes Association (ADA) recommends A1C testing to determine a patient’s average blood glucose control. For patients whose therapy has changed or who are not meeting glycemic goals, the A1C test should be performed quarterly. The A1C test should be performed at least two times a year in patients who are meeting treatment goals and who have stable glycemic control. Guidelines about A1C testing by the American Diabetes Association.

Naik Meditechs & Devices Pvt. Ltd. has the distribution rights for Bayers' A1Cnow+ Instrument in Ernakulam District. For more info log on to www.naikmeditechs.com

Omron Kerala, India – BP Monitors

2009-06-18T08:19:00.000-07:00

Omron launched its range of products in India back in August 2008.Naik Meditechs & Devices Pvt. Ltd. was selected as the marketing, sales, distribution and after-sales support partner for Omron.

The product that is going to sweep the market after the onslaught of Blood Glucose Monitors, which today is a common device at every home, is Blood Pressure Monitor.

Due to globalisation and a stressful working environment hypertension threatens to wallop the work force in India. According to a survey, 65 million people were affected by hypertension in 2008 in India and that in the years ahead it was likely to see a quantum leap of over 135 million to touch a figure of 200 million by 2015.

India is losing its potentially productive years due to increasing heart diseases, strokes and diabetes in the age group of 35-60, one of the highest in the world, according to the report.In the absence of proper facilities to mitigate propensities leading to tensions and high blood pressures, chronic diseases accounted for 53 per cent of deaths in the country and this was expected to go up to 60 per cent by 2015 and 66 per cent by 2020.

According to the report, 4 million deaths in 1990 were due to chronic diseases and the same was likely to touch a figure of 7 million by 2015.

Omron with its range of accurate, dependable and sturdy BP Monitors is all set to rule the roost.

Naik Meditechs had changed the health monitoring equipment market in Kerala by introducing the Roche Blood glucose monitoring equipment in this market. Its all set to do it again and this time with Omron BP Monitors.Met with a lot of skepticism, lack of product knowledge, awareness, low acceptance among doctors, patients, labs and distributors and retailers; Naik Meditechs embarked on a 12 month whirlwind tour of Kerala holding demo camps, giving at-home usage instructions and attending to problems personally.

With excellent brand awareness, brand communication, brand experience and after sales support as its back bone, Roche became the market leader in blood glucose monitoring and Roche Accu-chek Active almost became a generic brand name for Blood glucose monitoring systems.We are at the same scenario for BP Monitors as well, with people questioning the accuracy vis-a-vis the mercury sphygmomanometer.

We have initiated intensive campaigning at institutional, doctor and consumer level, educating and giving product experience to even doctors, nurses and medical shops.Omron BP monitors will be another feather in the cap for Naik Meditechs after Roche Accu-chek and Medtronic Minimed Insulin Pump.

For more information visit http://www.naikmeditechs.com/

Insulin Pump, Kerala

2009-06-12T21:58:00.000-07:00

Naik Meditechs brings to you the best of brands available in the world, in the health management and health monitoring sytems space.

Medtronic, Omron, Venosan, Lysoform, Olympus and Bayer Health Care are some of the brands we support.

Naik Meditechs & Devices Pvt. Ltd. was fortunate enough to get the marketing, sales, spares and after sales service rights in Kerala, India for Medtronic Minimed Insulin Pumps. This magic machine was received with a lot of enthusiasm with the diabetic population. After all it was a step forward in achieving their ultimate dream of living a normal life.

What is an insulin pump therapy?
An insulin pump is a small, battery-operated device (about the size of a pager) that can replace insulin injections for patients managing diabetes. The purpose of a pump is to provide an accurate, continuous controlled delivery of insulin, in pulses which can be regulated by the user to meet their Glucose control objectives.

How does an insulin pump work?
The pump delivers insulin from a reservoir inside the pump, through a thin plastic tube (called an infusion set), to the body. Most infusion sets are worn in the abdominal area and use a tiny, flexible tube, called a cannula, which is inserted easily into the skin using an insertion device. Patients generally refill their insulin and change their infusion sets every two to three days.
A pump is easy to program and automatically delivers a constant rate of insulin – called a “basal rate”- to keep blood glucose in the desired range between meals and over night. Guided by a physician, the user creates a customized basal pattern, with the goal of closely matching individual needs.

Pump users can easily adjust the pump for changes in lifestyle needs, and can program insulin delivery at mealtimes. Pump therapy is simple. It is based on what your body does naturally – deliver small pulses of insulin all the time and little extras controlled by the patient at mealtimes to cover the food intake.

The pump helps achieve “tight glucose control.” Diabetes patients can easily adjust insulin to keep glucose levels within a near-normal range. A pump can help patients avoid hyperglycaemia (high blood sugar), which can degrade health over time, and hypoglycaemia (low blood sugar), an acute condition that can be very dangerous, particularly at night while a patient sleeps. The pump more closely mimics a healthy pancreas.

An insulin pump more closely mimics a healthy pancreas by delivering insulin effectively, continuously and with minimal variability. A healthy pancreas delivers insulin every 10 to 14 minutes. A pump more closely mimics the pancreas by continually delivering insulin around the clock and allowing patients to program multiple basal rates depending on their individual needs.
The pump is precise and accurate. Insulin pumps can deliver insulin precisely and accurately in 0.1 unit increments, which is nearly impossible for people using traditional injection therapy. With the pump, people can be more flexible.

Unlike patients using longer-acting insulin with injection therapy who must follow rigid schedules of insulin injections, meals and snacks, patients using an insulin pump can program insulin delivery when they eat, and adjust or stop insulin delivery for exercise or other needs. Patients using pump therapy can eat what they want, when they want — something almost unheard of in patients treating their condition with traditional insulin injections.

India - the Diabetes Capital of the World

India – over 35 million are affected making it the diabetic capital of the world and approx 2 – 3% have Type 1 diabetes
Every fourth diabetic in the world today is an Indian.
Indians are genetically more susceptible to diabetes and the number of diabetics in India would go up to 40 million by 2010 and 74 million by 2025
Diabetes is a life-threatening condition.
One in 20 deaths is attributable to diabetes; 8,700 deaths every day; six deaths every minute
Diabetes has become one of the major causes of premature illness and death in most countries, mainly through the increased risk of cardiovascular disease (CVD). Cardiovascular disease is responsible for between 50% and 80% of deaths in people with diabetes.

For more information on Insulin pumps visit www.naikmeditechs.com
or visit http://www.medtronic.com/IN/about/businesses.html